跳轉至內容
Merck
全部照片(1)

重要文件

檢視所有文件

F1308

Sigma-Aldrich

福辛普利 钠

≥98% (HPLC), powder

同義詞:

(2S,4S)-4-Cyclohexyl-1-(2-{[2-methyl-1-(propanoyloxy)propoxy](4-phenylbutyl)phosphoryl}acetyl)pyrrolidine-2-carboxylic acid, Acecor, Eosinopril, Fosinopril, Monopril, SQ 28555, Secorvas, Staril

登入查看組織和合約定價
全部照片(1)

About This Item

經驗公式（希爾表示法）:
C30H45NO7P · Na
CAS號碼:
88889-14-9
分子量：:
585.64
MDL號碼:
MFCD23704184
分類程式碼代碼:
12352200
PubChem物質ID:
329799677
NACRES:
NA.77

品質等級

100

化驗

≥98% (HPLC)

形狀

powder

儲存條件

desiccated

顏色

white to off-white

溶解度

H2O: >20 mg/mL

起源

Bristol-Myers Squibb

儲存溫度

−20°C

SMILES 字串

O=C([O-])[C@H]1N(C(CP(CCCCC2=CC=CC=C2)(O[C@@H](C(C)C)OC(CC)=O)=O)=O)C[C@H](C3CCCCC3)C1.[Na+]

InChI

1S/C30H46NO7P.Na/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24;/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35);/q;+1/p-1/t25-,26+,30+,39?;/m1./s1

InChI 密鑰

TVTJZMHAIQQZTL-TXDYNIFHSA-M

尋找類似的產品？ 前往 產品比較指南

一般說明

Fosinopril lowers blood pressure and functions as an antihypertensive agent. It is an ester prodrug. Fosinopril is metabolised by the liver and excreted from the body by liver and kidney. It is used to treat heart failure.

生化／生理作用

Fosinopril is an angiotensin converting enzyme (ACE) inhibitor.
Fosinopril is an angiotensin converting enzyme (ACE) inhibitor. Fosinopril is also known to inhibit the activity of the peptide transporter PEPT2.

特點和優勢

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

象形圖

Health hazardExclamation mark
GHS08,GHS07

訊號詞

Warning

危險聲明

H319,H361d

危險分類

Eye Irrit. 2 - Repr. 2

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

從最近期的版本中選擇一個：

分析證明 (COA)

Lot/Batch Number
101M4742V
021M4715V

未看到正確版本？

如果您需要一個特定的版本，您可以透過批號來尋找特定憑證。

搜尋 COA

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Abhishek S Chitnis et al.
Research in social & administrative pharmacy : RSAP, 8(2), 145-156 (2011-04-23)
Heart failure is a major and growing public health problem in United States. There is a substantial evidence about efficacy of angiotensin-converting enzyme inhibitors (ACEIs) in heart failure (HF); however, there is no conclusive evidence on the relative effectiveness of
Lakhan Kma et al.
Journal of radiation research, 53(1), 10-17 (2012-02-04)
Our long-term goal is to use angiotensin converting enzyme (ACE) inhibitors to mitigate the increase in lung collagen synthesis that is induced by irradiation to the lung, which could result from accidental exposure or radiological terrorism. Rats (WAG/RijCmcr) were given
Giuseppe Mancia et al.
BMJ (Clinical research ed.), 340, c1197-c1197 (2010-03-27)
To investigate the possibility that statins reduce blood pressure as well as cholesterol concentrations through clinic and 24 hour ambulatory blood pressure monitoring. Randomised placebo controlled double blind trial. 13 hospitals in Italy 508 patients with mild hypertension and hypercholesterolaemia
Tie Zhao et al.
Journal of pharmaceutical and biomedical analysis, 60, 32-43 (2011-12-14)
The pathological development of diabetic kidney disease (DKD) might involve metabolic perturbations in kidney tissue. The present study was designed to detect the systematic alterations of renal cortex metabolites thereby exploring the related mechanisms of DKD development and fosinopril treatment.
Current Cardiovascular Drugs (2005)
查看所有相關論文

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務